[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anca-associated-glomerulonephritis-aagn\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anca-associated-glomerulonephritis-aagn":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100650118","phase-2-obinutuzumab-beta-combined-with-low-dose-glucocorticoid-in-new-onset-anca-associated-glomerulonephritis-100650118",false,"NCT07746180","Obinutuzumab Beta Combined With Low-dose Glucocorticoid in New-onset ANCA-Associated Glomerulonephritis","Obinutuzumab Beta Combined With Low-dose Glucocorticoid in New-onset ANCA-Associated Glomerulonephritis: A Prospective Exploratory Study","Inclusion Criteria:\n\n* New diagnosis of ANCA-associated vasculitis (Granulomatosis with polyangiitis \\[GPA\\] or Microscopic polyangiitis \\[MPA\\]) according to the Chapel Hill Consensus Conference definitions.\n* Positive for PR3-ANCA or MPO-ANCA.\n* Active renal involvement indicated by recent renal biopsy (pauci-immune necrotizing and\u002For crescentic glomerulonephritis) OR active urine sediment characterized by glomerular hematuria and proteinuria.\n* Provided signed informed consent.\n\nExclusion Criteria:\n\n* Prior treatment with targeted B-cell therapies (e.g., Rituximab) or standard cyclophosphamide, azathioprine, or mycophenolate mofetil for AAV.\n* Current requirement for dialysis, or history of dialysis.\n* Presence of life-threatening acute vasculitis manifestations other than renal involvement (e.g., diffuse alveolar hemorrhage, respiratory failure, bowel perforation, cerebral vasculitis).\n* History of malignancy within the past 5 years.\n* Coexisting multisystem autoimmune diseases (e.g., systemic lupus erythematosus, anti-GBM disease).\n* Active severe infections, active tuberculosis, or chronic viral infections (HBV with positive HBsAg or HBV-DNA, active HCV, HIV).\n* Pregnant or lactating women.","ALL","18 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This study is an open-label, single-arm, exploratory study designed to evaluate the efficacy and safety of Obinutuzumab beta combined with a rapid-tapering glucocorticoid regimen in patients with new-onset ANCA-associated glomerulonephritis (AAGN).",[26,27],"ANCA-Associated Glomerulonephritis (AAGN)","ANCA-Associated Vasculitis (AAV)",[26,29,30],"Obinutuzumab beta","Glucocorticoid","NOT_YET_RECRUITING","2026-07-30",{"date":34,"type":35},"2026-08-04","ACTUAL",{"date":37,"type":20},"2026-07-31",{"date":39,"type":20},"2029-03-30",{"name":41,"class":42},"Chinese PLA General Hospital","OTHER"]